Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation

被引:82
作者
Poynard, T.
Halfon, P.
Castera, L.
Charlotte, F.
Le Bail, B.
Munteanu, M.
Messous, D.
Ratziu, V.
Benhamou, Y.
Bourliere, M.
De Ledinghen, V.
机构
[1] Grp Hosp Pitie Salpetriere, AP HP, F-75651 Paris 13, France
[2] Alphabio, Marseille, France
[3] CHU Bordeaux, Bordeaux, France
[4] Biopredictive, Paris, France
[5] St Joseph Hosp, Marseille, France
关键词
D O I
10.1111/j.1365-2036.2007.03252.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The area under the receiver operating characteristic (ROC) curve is widely used as an estimate of the diagnostic value for fibrosis markers. Biopsy length and fragmentation are known as risk factors of false positive or false negative of biopsy but their quantitative impact on area under the receiver operating characteristic curve variability has not been assessed. Aim To assess these relationships to better compare the fibrosis markers. Methods The area under the ROC curves of FibroTest for the diagnosis of fibrosis was estimated in patients with chronic hepatitis C using an integrated database including 1312 patients with FibroTest and biopsy. To take into account the biopsy length, we used two adjustment factors: one in which an observed area under the ROC curve could be adjusted according to the relative area under the receiver operating characteristic curve of a biopsy of a given length vs. the entire liver and one taking into account the prevalence of each fibrosis stage defining advanced and non-advanced fibrosis. Results The mean biopsy length was smaller for cirrhosis (F4, 16 mm) vs. F3, (18 mm, P = 0.01) and FO (19 mm, P = 0.01). The mean number of fragments was higher for cirrhosis (F4 4.1 fragments) vs. all the other stages (F0 = 1.9, F1 = 1.9, F2 = 1.9, F3 2.3; P < 0.001 vs. F4). The FibroTest area under the ROC curves for the diagnosis of advanced fibrosis, adjusted for stages' prevalence, ranged from 0.80 to 0.98 depending on biopsy length and fragmentation, respectively. Conclusion The comparison of the area under the ROC curves of fibrosis markers should take into account the biopsy length and fragmentation.
引用
收藏
页码:733 / 739
页数:7
相关论文
共 18 条
[1]   Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? [J].
Afdhal, NH .
HEPATOLOGY, 2003, 37 (05) :972-974
[2]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[3]   Sampling variability of liver fibrosis in chronic hepatitis C [J].
Bedossa, P ;
Dargère, D ;
Paradis, V .
HEPATOLOGY, 2003, 38 (06) :1449-1457
[4]   Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease [J].
Colloredo, G ;
Guido, M ;
Sonzogni, A ;
Leandro, G .
JOURNAL OF HEPATOLOGY, 2003, 39 (02) :239-244
[5]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[6]   Role of liver biopsy in management of chronic hepatitis C: A systematic review [J].
Gebo, KA ;
Herlong, HF ;
Torbenson, MS ;
Jenckes, MW ;
Chander, G ;
Ghanem, KG ;
El-Kamary, SS ;
Sulkowski, M ;
Bass, EB .
HEPATOLOGY, 2002, 36 (05) :S161-S172
[7]   Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: The fibropaca study [J].
Halfon, P ;
Bourliere, M ;
Deydier, R ;
Botta-Fridlund, D ;
Renou, C ;
Tran, A ;
Portal, I ;
Allemand, I ;
Bertrand, JJ ;
Rosenthal-Allieri, A ;
Rotily, M ;
Sattonet, C ;
Benderitter, T ;
Paul, MCS ;
Bonnot, HP ;
Penaranda, G ;
Degott, C ;
Masseyeff, MF ;
Ouzan, D .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (03) :547-555
[8]  
Klatskin G, 1993, HISTOPATHOLOGY LIVER
[9]   Biomarkers as a first-line estimate of injury in chronic liver diseases: Time for a moratorium on liver biopsy? [J].
Poynard, T ;
Ratziu, V ;
Benhamou, Y ;
Thabut, D ;
Moussalli, J .
GASTROENTEROLOGY, 2005, 128 (04) :1146-1148
[10]   Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C [J].
Poynard, T ;
Munteanu, M ;
Imbert-Bismut, F ;
Charlotte, F ;
Thabut, D ;
Le Calvez, S ;
Messous, D ;
Thibault, V ;
Benhamou, Y ;
Moussalli, J ;
Ratziu, V .
CLINICAL CHEMISTRY, 2004, 50 (08) :1344-1355